Freedom Biosciences Raises $10.5M in Seed Financing
- Freedom Biosciences, a San Francisco, CA-based provider of a clinical-stage biotechnology platform to advance ketamine and psychedelic therapeutics, raised $10.5M in Seed funding
- The round was led by MBX Capital with participation from PsyMed Ventures, Village Global and The Yale Startup
- The company intends to use the funds to advance its current lead ketamine program as well as further multiple additional exploratory programs
- FreedomBiosciences is a clinical-stage biotechnology platform developing viable and efficacious ketamine and psychedelic therapeutics
- The company’s FREE001 is a ketamine treatment that’s been demonstrated in clinical trials to have more durable effects than ketamine
- A Phase 2 investigational study showed that the combination provided 14 days of antidepressant effects, 2 to 3 times longer than the usual 2-7 days of effects from ketamine alone
